HC Wainwright Has Positive Forecast for OLMA Q1 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Equities researchers at HC Wainwright lifted their Q1 2025 earnings estimates for Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.59) per share for the quarter, up from their previous forecast of ($0.64). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals' Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($3.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($3.10) EPS.

Separately, Oppenheimer reaffirmed an "outperform" rating and set a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Olema Pharmaceuticals Trading Down 3.0 %

OLMA stock traded down $0.13 during mid-day trading on Friday, reaching $4.19. The company's stock had a trading volume of 541,869 shares, compared to its average volume of 816,924. Olema Pharmaceuticals has a 12 month low of $3.94 and a 12 month high of $16.62. The business's 50 day moving average price is $5.08 and its 200 day moving average price is $8.25. The company has a market cap of $240.08 million, a price-to-earnings ratio of -1.91 and a beta of 2.11.

Remove Ads

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12.

Institutional Investors Weigh In On Olema Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its position in shares of Olema Pharmaceuticals by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company's stock valued at $1,941,000 after buying an additional 2,189 shares during the last quarter. EP Wealth Advisors LLC boosted its holdings in Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company's stock worth $581,000 after acquiring an additional 2,407 shares during the last quarter. Boothbay Fund Management LLC grew its stake in shares of Olema Pharmaceuticals by 10.8% in the 4th quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company's stock worth $182,000 after acquiring an additional 3,056 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Olema Pharmaceuticals by 43.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company's stock worth $62,000 after acquiring an additional 3,185 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Olema Pharmaceuticals by 30.2% in the fourth quarter. ProShare Advisors LLC now owns 14,226 shares of the company's stock valued at $83,000 after purchasing an additional 3,298 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Insider Buying and Selling at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, January 8th. The stock was purchased at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the acquisition, the insider now directly owns 7,800,000 shares of the company's stock, valued at $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 19.40% of the company's stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.